Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
NCT07493330
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
86
Enrollment
OTHER
Sponsor class
Conditions
PTCL
Refractory
Interventions
DRUG:
Zeprumetostat+Azacitadine
DRUG:
Zeprumetostat+Decitabine
DRUG:
Zeprumetostat+Chidamide
DRUG:
Zeprumetostat+Golidocitinib
Sponsor
Ruijin Hospital